Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gaviscon Advance for proton pump inhibitor washout in GERD
2022-003716-91Phase 4Completed
- Sponsor
- Centrum Gastroenterologie Bethanien
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of gaviscon advance in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Centrum Gastroenterologie Bethanien. Primary endpoint: Change in GERD-HRQL 16-item efficacy sum score. Started Dec 2022; status: completed.
02
Drugs
gaviscon advance
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on 2022-003716-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003716-91.